- Asked by: Mary Scanlon, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
-
Date lodged: Monday, 25 November 2002
-
Current Status:
Answered by Malcolm Chisholm on 9 December 2002
To ask the Scottish Executive what the projected year-end surplus or deficit is of each acute hospital NHS trust.
Answer
The forecast financial position of the acute NHS trusts as at 30 September 2002 was as follows:
| Trust | Forecast Full Year Under/(Over) Spend Against Revenue Resource Limit(£000) |
| Argyll and Clyde Acute | (3,689) |
| Ayrshire and Arran Acute | (1,200) |
| Borders General Hospital | 60 |
| Dumfries and Galloway Acute | (300) |
| Fife Acute Hospitals | (1,490) |
| Forth Valley Acute | 123 |
| Grampian University Hospitals | (4,000) |
| North Glasgow University Hospitals | 2,128 |
| South Glasgow University Hospitals | 0 |
| Yorkhill | 175 |
| Highland Acute | (1,284) |
| Lanarkshire Acute | (763) |
| Lothian University Hospitals | 0 |
| West Lothian Healthcare | (1,520) |
| Tayside University Hospitals | 0 |
The figures in the table are taken from the September 2002 monthly monitoring reports.Those NHS trusts which were forecasting to overspend against their revenue resource limit are working with their local NHS boards, Primary Care NHS Trusts and the Scottish Executive Health Department in order to return to financial balance whilst protecting patient services.
- Asked by: Mary Scanlon, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
-
Date lodged: Monday, 25 November 2002
-
Current Status:
Answered by Malcolm Chisholm on 9 December 2002
To ask the Scottish Executive what the involvement of (a) patient groups and (b) the voluntary and independent sector will be in the development of managed clinical networks.
Answer
Patient groups and the voluntary and independent sectors have a central role to play in the development of managed clinical networks. As our Health Department Letter (HDL(2002)69) indicates, involving patients is one of the core principles of managed clinical network development. The letter also points out that the value of patient representation at all stages of managed clinical network development has been clearly demonstrated.
- Asked by: Mary Scanlon, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
-
Date lodged: Monday, 25 November 2002
-
Current Status:
Answered by Frank McAveety on 9 December 2002
To ask the Scottish Executive whether there are waiting lists for (a) home and (b) residential care services in local authorities and, if so, how long each such list is.
Answer
The information requested is not held centrally.
- Asked by: Mary Scanlon, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
-
Date lodged: Monday, 25 November 2002
-
Current Status:
Answered by Malcolm Chisholm on 9 December 2002
To ask the Scottish Executive whether funding under the Arbuthnott formula was due to be allocated over three years and how much of this funding has been given to each NHS board to date.
Answer
The Executive's plans for implementing the recommendations in Fair Shares for All indicated that the aim was for all boards to reach their Arbuthnott share of resources within five or six years.Since the introduction of the Arbuthnott formula in September 2000, all boards have received a minimum increase in unified budget with those boards below their Arbuthnott share receiving additional funding. To date, additional funds totalling £71.2 million have been allocated to boards currently below their Arbuthnott share.
- Asked by: Mary Scanlon, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
-
Date lodged: Monday, 25 November 2002
-
Current Status:
Answered by Frank McAveety on 9 December 2002
To ask the Scottish Executive what the cost of fraudulent claims in the NHS has been in each of the last five years.
Answer
NHS trusts and boards complete a losses return at the year-end as part of the annual accounts process. Fraud losses are reported alongside losses arising from theft and arson, so it is not possible to identify a figure for fraud alone.The following table summarises the totals reported by NHS boards for theft, fraud, and arson in the last five financial years and the equivalent totals reported by NHS trusts for the last three financial years.Theft, Fraud and Arson Losses Reported
| 2001-02(£) | 2000-01(£) | 1999-00(£) | 1998-99(£) | 1997-98(£) |
| NHS Trusts | 44,345 | 75,625 | 106,406 | Not Available |
| NHS Boards | 3,746 | 21,840 | 23,296 | 40,120 | 18,742 |
| Total | 48,091 | 97,465 | 129,702 | Not Available |
In addition, since its establishment in July 2000, NHSScotland Counter Fraud Services of the Common Services Agency (formerly the Fraud Investigation Unit) has identified losses to family health services from false or inappropriate payment claims of £98,027 in 2000-01 and £100,924 in 2001-02.
- Asked by: Mary Scanlon, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
-
Date lodged: Monday, 25 November 2002
-
Current Status:
Answered by Malcolm Chisholm on 9 December 2002
To ask the Scottish Executive what managed clinical networks are (a) currently being developed and (b) proposed.
Answer
We already have practical examples of managed clinical networks (MCN) at local, regional and national level. There is the cardiac services MCN in Dumfries and Galloway, the diabetes MCN in Tayside, the regional cancer MCNs and national MCNs for cleft lip and palate and home parenteral nutrition. Two demonstration MCNs, one in vascular services and one in neurology with particular reference to stroke, are being evaluated.A wide range of MCN development is being taken forward, covering conditions such as multiple sclerosis, epilepsy, asthma, chronic obstructive pulmonary disorder, hepatitis C and primary immunodeficiency, as well as in areas such as pathology, mental health, learning disabilities and medical receiving in community hospitals.The CHD/Stroke Strategy makes clear that each NHS board should have a cardiac services and a stroke MCN in operation by April 2004. The Scottish Diabetes Framework has a milestone that by September 2004 Managed Clinical Networks for Diabetes will be established in each NHS board area.
- Asked by: Mary Scanlon, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
-
Date lodged: Monday, 25 November 2002
-
Current Status:
Answered by Malcolm Chisholm on 9 December 2002
To ask the Scottish Executive to whom the managers of managed clinical networks will be accountable.
Answer
Network managers are accountable to the Lead Clinician of the managed clinical network.
- Asked by: Mary Scanlon, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
-
Date lodged: Friday, 22 November 2002
-
Current Status:
Answered by Malcolm Chisholm on 5 December 2002
To ask the Scottish Executive, further to the answer to question S1W-31271 by Malcolm Chisholm on 18 November 2002, how many patients it estimates would undertake anticoagulation self-monitoring if monitoring strips were to be made available under the Scottish Drug Tariff.
Answer
Information about the number of patients receiving treatment with anticoagulants is not available. Self-monitoring will not be appropriate for all patients who are receiving anticoagulation therapy. Selection of patients suitable for self monitoring is a matter for the responsible medical practitioner.
- Asked by: Mary Scanlon, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
-
Date lodged: Friday, 22 November 2002
-
Current Status:
Answered by Malcolm Chisholm on 5 December 2002
To ask the Scottish Executive, further to the answer to question S1W-31271 by Malcolm Chisholm on 18 November 2002, how the appropriate guidance for users of CoaguChek testing strips is likely to differ from that already provided by the British Society of Haematology to NHS prescribers and dispensing contractors in England, Wales and Northern Ireland where strips are already available on prescription, and when it expects to finalise such guidance.
Answer
British Society of Haematology guidance on the use of Coaguchek testing strips was published in the British Medical Journal in October 2001. The article included a recommendation that the guidance be reviewed in April this year. A multidisciplinary working group was convened in May 2002 to review all previous guidance, and produce guidance from a prescribing practitioner perspective in the context of services to patients via NHS Scotland. This is now available on www.show.scot.nhs.uk and Coaguchek testing strips were added to the Scottish Drug Tariff on 27 November.
- Asked by: Mary Scanlon, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
-
Date lodged: Friday, 22 November 2002
-
Current Status:
Answered by Malcolm Chisholm on 5 December 2002
To ask the Scottish Executive, further to the answer to question S1W-31271 by Malcolm Chisholm on 18 November 2002, what the estimated savings are to the NHS of prescribing self-monitoring anticoagulation strips given that such strips cost #2.44 and the estimated cost of a laboratory test for an identical blood sample is #80.
Answer
It is not possible to produce an estimate of the savings as the number of patients currently receiving treatment with anticoagulants is not available. The number of patients likely to be prescribed Coaguchek testing strips is unknown.
